Synlogic stock.
Synlogic beat estimated earnings by 3.75%, reporting an EPS of $-2.57 versus an estimate of $-2.67. Revenue was down $285 thousand from the same period last year. Past Earnings Performance
Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis. If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Nov 24, 2023 · Support, Risk & Stop-loss for Synlogic Inc stock. On the downside, the stock finds support just below today's level from accumulated volume at $2.14 and $2.07. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. Nov 9, 2023 · Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options ... Share. Share. Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering. Stock Information for Synlogic Inc. Loading. Please wait while we ...
Nowadays finding high-quality stock photos for personal or commercial use is very simple. You just need to search the photo using a few descriptive words and let Google do the rest of the work.
Synlogic Inc. analyst ratings, historical stock prices, earnings estimates & actuals. SYBX updated stock price target summary.
Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of 19.23% and 80.56%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?Starting us off today is Twist Biosciences. In brief, Twist is a leading name in the synthetic biology industry today. The company’s core work revolves around its proprietary DNA synthesis ...Since its IPO on the Shenzhen stock exchange, its share price has gone up every day by the exact same amount. Baofeng Technologies is China’s best performing stock this year. Since its IPO on the Shenzhen stock exchange, its share price has...Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.
Share. Share. Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering. Stock Information for Synlogic Inc. Loading. Please wait while we ...
Website. n/a. 72. Aoife Brennan. https://www.synlogictx.com. Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic and immunological diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate ...
Ginkgo has purchased 6,340,771 shares of Synlogic common stock as well as pre-funded warrants to purchase up to 2,548,117 shares of Synlogic common stock, both at a price of $9.00 per share. Gross proceeds to Synlogic are approximately $80 million. The transactions were executed and closed on June 11, 2019.Get Synlogic Inc (SYBX.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsTo take any of these actions regarding your Synlogic stock, please contact the American Stock Transfer & Trust Company, LLC, Synlogic’s transfer agent. Some of these requests may involve a fee. American Stock Transfer & Trust Company (800) 937-5449 (Toll-free) (718) 921-8124 (International)The last twelve months weren't great for Synlogic shares, which cost holders 12%, while the market was up about 15%. Of course the long term matters more than the short term, and even great stocks ...Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...On August 25, 2017, in connection with, and prior to the completion of the Merger, Mirna effected a reverse stock split of its common stock (the “Reverse Stock Split”), and on August 28, 2017, immediately after completion of the Merger, Mirna changed its name to “Synlogic, Inc.” (NASDAQ: SYBX).May 24, 2023 · CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 30 – June 2, 2023 in Los Angeles, CA.
May 24, 2023 · CAMBRIDGE, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced its planned presentations at the 2023 Synthetic Biology: Engineering, Evolution & Design (SEED) conference being held May 30 – June 2, 2023 in Los Angeles, CA. According to 2 stock analysts, the average 12-month stock price forecast for Synlogic stock is $82.5, which predicts an increase of 3,122.66%. The lowest target is $75 and the highest is $90. On average, analysts rate Synlogic stock as a strong buy.Synlogic Inc (SYBX). Sector: HEALTH CARE. Industry: BIOTECHNOLOGY & LIFE SCIENCES. SIC: PHARMACEUTICAL ... Stock Lookup. Enter stock name: use * for wildcard.Complete Synlogic Inc. stock information by Barron's. View real-time SYBX stock price and news, along with industry-best analysis. Chg %. Market Cap. Molecular Templates Inc. 4.65%. $33.48M. SYBX | Complete Synlogic Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full …Third Quarter 2023 Financial Results and Financial Outlook. As of September 30, 2023, Synlogic had cash, cash equivalents and short-term investments of $33.4 million, not inclusive of the October financing of $19.6 million (net), and an additional $2.5 million earned from the Roche research collaboration milestone announced in November.
CAMBRIDGE, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non …
Analyst Keay Nakae of Chardan Capital reiterated a Buy rating on Synlogic (SYBX – Research Report), with a price target of $35.00. Keay Nakae’s Buy rating for Synlogic is rooted in several ...According to 2 analysts, the average rating for SYBX stock is "Strong Buy." The 12-month stock price forecast is $82.5, which is an increase of 3,351.88% from the latest price.To take any of these actions regarding your Synlogic stock, please contact the American Stock Transfer & Trust Company, LLC, Synlogic’s transfer agent. Some of these requests may involve a fee. American Stock Transfer & Trust Company (800) 937-5449 (Toll-free) (718) 921-8124 (International) [email protected] daily share price chart and data for Synlogic since 2015 adjusted for splits and dividends. The latest closing stock price for Synlogic as of November 27, 2023 is 1.97.. …A. Synlogic ( SYBX) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $393K, which beat ...Synlogic, Inc. CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed ...
Synlogic Inc SYBX Morningstar Rating Unlock Stock XNAS Rating as of Nov 17, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation Operating...
Synlogic, Inc. CAMBRIDGE, Mass., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed ...
Synlogic Inc stocks price quote with latest real-time prices, charts, financials, latest news, ... Do the numbers hold clues to what lies ahead for the stock? SYBX: 0.8376 (-3.60%) ROIV: 5.14 (-2.10%) Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks PR Newswire - Thu Aug 11, 6:05AM CDTView live Synlogic, Inc. chart to track its stock's price action. Find market predictions, SYBX financials and market news.So should Synlogic (NASDAQ:SYBX) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...INMB stock currently trades for $7.80 and reached a 52-week high of $11.78 while carrying an average target stock price of $18.00. Synlogic (SYBX) Biotechnology stocks, biomedical stocks.Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update. ... Stock in Plug Power continues to lose support on Wall Street, ...Nov 30, 2022 · Synlogic has also developed two drug candidates through a research collaboration with Ginkgo Bioworks: SYNB1353, designed to consume methionine for the potential treatment of HCU, and SYNB2081, designed to lower uric acid for the potential treatment of gout. Mar 24, 2021 · CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB8802 has achieved proof of mechanism in a Dietary Hyperoxaluria study in which healthy volunteers on a high oxalate and low calcium diet were treated with multiple ascending doses of SYNB8802. Get the latest Synlogic, Inc. (SYBX) stock news and headlines to help you in your trading and investing decisions.On average, Wall Street analysts predict. that Synlogic's share price could reach $82.50 by Aug 11, 2024. The average Synlogic stock price prediction forecasts a potential upside of 4,025% from the current SYBX share price of $2.00.
Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Stock Information. Stock Quote & Chart; Analyst Coverage; Corporate Governance. Governance Highlights; Management Team; Board of Directors; Committee …Instagram:https://instagram. florida short term health insuranceglaxo smithkline share priceflorida fine cars orlandocharles schwab buys td ameritrade Synlogic to Implement 1-for-15 Reverse Stock Split Sep. 28: MT Earnings Flash (SYBX) SYNLOGIC Posts Q2 Revenue $35,000 Aug. 10: MT Synlogic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 ... Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in … tesla price cutkennedy 1971 half dollar value Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.Synlogic, Inc. (SYBX) Reports Q3 Loss, Tops Revenue Estimates Zacks - Thu Nov 10, 2022 . Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? blackstone and blackrock SYNLOGIC INVESTOR CONTACT: Daniel Rosan Synlogic, Inc. 617-401-9152 [email protected] SYNLOGIC MEDIA CONTACT: Jenna Urban Berry & Company Public Relations 212-253-8881 [email protected]Synlogic, Inc. (SYBX) delivered earnings and revenue surprises of -8.70% and 93.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?Synlogic, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing therapeutics based on synthetic biology. Its pipeline includes its program in phenylketonuria (PKU), and additional drug candidates designed to treat homocystinuria (HCU), enteric hyperoxaluria and gout.